---
figid: PMC6074780__itt-7-063Fig1
figtitle: 'PD-1 in T-cell activation, exhaustion and effector function.Notes: (A)
  T-cells are activated via (1) binding of MHC plus peptide on an APC to the TCR and
  then (2) binding of APC CD80/86 to T-cell CD28'
organisms:
- NA
pmcid: PMC6074780
filename: itt-7-063Fig1.jpg
figlink: /pmc/articles/PMC6074780/figure/f1-itt-7-063/
number: F1
caption: 'PD-1 in T-cell activation, exhaustion and effector function.Notes: (A) T-cells
  are activated via (1) binding of MHC plus peptide on an APC to the TCR and then
  (2) binding of APC CD80/86 to T-cell CD28. In patients with cancer, tumor cells
  can also serve as APCs. Upon T-cell activation, PD-1 expression is induced. (B)
  In situations of chronic infection or persistent stimulation, PD-L1 signals through
  T-cell PD-1 to “turn off” T-cells in order to minimize damage to healthy tissue.
  Tumor cells can upregulate PD-L1 in order to “turn off” T-cells that might destroy
  them. (C) Blocking the PD-1/PD-L1 signaling pathway allows T-cells to maintain their
  effector functions. In patients with cancer, activated tumor-specific T-cells can
  kill tumor cells and secrete cytokines that activate/recruit other immune cells
  to participate in the antitumor response. Reproduced under Creative Commons Attribution
  License (CC BY), from McDermott DF, Atkins MB. PD-1 as a potential target in cancer
  therapy. Cancer Med. 2013;2(5):662–673. © 2013 The Authors. Cancer Medicine published
  by John Wiley.Abbreviations: APC, antigen-presenting cell; IFN-γ, interferon gamma;
  MHC, major histocompatibility complex; PD-1, programmed death-1; PD-L1, PD ligand
  1; TCR, T-cell receptor.'
papertitle: Review of checkpoint immunotherapy for the management of non-small cell
  lung cancer.
reftext: Shine Raju, et al. Immunotargets Ther. 2018;7:63-75.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9204139
figid_alias: PMC6074780__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC6074780__F1
ndex: f5af4c35-de99-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6074780__itt-7-063Fig1.html
  '@type': Dataset
  description: 'PD-1 in T-cell activation, exhaustion and effector function.Notes:
    (A) T-cells are activated via (1) binding of MHC plus peptide on an APC to the
    TCR and then (2) binding of APC CD80/86 to T-cell CD28. In patients with cancer,
    tumor cells can also serve as APCs. Upon T-cell activation, PD-1 expression is
    induced. (B) In situations of chronic infection or persistent stimulation, PD-L1
    signals through T-cell PD-1 to “turn off” T-cells in order to minimize damage
    to healthy tissue. Tumor cells can upregulate PD-L1 in order to “turn off” T-cells
    that might destroy them. (C) Blocking the PD-1/PD-L1 signaling pathway allows
    T-cells to maintain their effector functions. In patients with cancer, activated
    tumor-specific T-cells can kill tumor cells and secrete cytokines that activate/recruit
    other immune cells to participate in the antitumor response. Reproduced under
    Creative Commons Attribution License (CC BY), from McDermott DF, Atkins MB. PD-1
    as a potential target in cancer therapy. Cancer Med. 2013;2(5):662–673. © 2013
    The Authors. Cancer Medicine published by John Wiley.Abbreviations: APC, antigen-presenting
    cell; IFN-γ, interferon gamma; MHC, major histocompatibility complex; PD-1, programmed
    death-1; PD-L1, PD ligand 1; TCR, T-cell receptor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CD274
  - APC
  - PROC
  - CD28
  - HLA-C
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - CD80
  - CD86
  - TCR
  - Chronic infection
  - Cytotoxicity
  - APC
---
